Oral hypoglycaemic drugs help control blood-glucose levels by reducing insulin resistance (metformin), stimulating insulin production (sulfonylureas), increasing insulin sensitivity (rosiglitazone), acting as an α-amylase inhibitor (acarbose), acting as α-glucosidase inhibitors (acarbose, voglibose, miglitol), and acting as a DPP-IV inhibitor (gliptins) [6,7,8,9,10,11,12,13,14]. Here, INS is linked to Insulin resistance.